These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2010105)

  • 1. A newly developed in vitro chemosensitivity test (nuclear damage assay): application to ovarian cancer.
    Sekiya S; Iijima N; Oosaki T; Takamizawa H; Tokita H
    Gynecol Oncol; 1991 Feb; 40(2):138-43. PubMed ID: 2010105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Result of individualized chemotherapy with a newly developed in vitro chemosensitivity testing in ovarian cancer].
    Iijima N; Sekiya S; Tokita H; Oosaki T; Takamizawa H
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Oct; 43(10):1323-8. PubMed ID: 1955784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Basic study on in vitro chemosensitivity tests].
    Iijima N; Sekiya S; Tokita H; Takamizawa H
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Feb; 43(2):191-6. PubMed ID: 2013708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay.
    Simmonds AP; McDonald EC
    Br J Cancer; 1984 Sep; 50(3):317-26. PubMed ID: 6540594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
    Sevin BU; Perras JP
    Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X; Lou LG; Sui DH; Wu XH
    Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intensity regimens with epirubicin in ovarian cancer.
    Vermorken JB
    Pathol Biol (Paris); 1992 Nov; 39(9):833. PubMed ID: 1538894
    [No Abstract]   [Full Text] [Related]  

  • 9. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
    Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
    Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
    O'Meara AT; Sevin BU
    Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
    Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment.
    Wilson AP; Ford CH; Newman CE; Howell A
    Br J Cancer; 1987 Dec; 56(6):763-73. PubMed ID: 3435704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
    Gerhardt RT; Perras JP; Sevin BU; Petru E; Ramos R; Guerra L; Averette HE
    Am J Obstet Gynecol; 1991 Aug; 165(2):245-55. PubMed ID: 1872324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
    Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
    Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.
    Harstrick A; Schmoll HJ; Sass G; Poliwoda H; Rustum Y
    Eur J Cancer; 1993; 29A(7):1000-2. PubMed ID: 8499130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
    Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.